Roivant Secures FDA Nod for Dermatomyositis Drug LISRAYA
Event summary
- FDA approves Roivant's LISRAYA (brepocitinib) for adult dermatomyositis, a rare autoimmune disease.
- LISRAYA is the first targeted therapy for dermatomyositis, offering steroid-sparing benefits and improved disease activity.
- The approval follows the VALOR trial, the largest dermatomyositis clinical trial ever conducted.
- LISRAYA is now available in the U.S., with a patient support program offering $0 monthly cost for eligible patients.
- Roivant plans to discuss the updates in an investor call on August 28, 2026.
The big picture
Roivant's FDA approval for LISRAYA marks a significant milestone in the treatment of dermatomyositis, a debilitating autoimmune disease with limited therapeutic options. The approval underscores the potential of targeted therapies in rare diseases and positions Roivant as a key player in the biopharmaceutical sector. The company's focus on advancing its late-stage pipeline further highlights its strategic shift towards becoming a fully integrated biopharmaceutical company.
What we're watching
- Pipeline Expansion
- Whether Roivant can replicate LISRAYA's success in other late-stage programs, including non-infectious uveitis and cutaneous sarcoidosis.
- Market Penetration
- The pace at which LISRAYA gains adoption among dermatomyositis patients, given its status as the first targeted therapy for the condition.
- Commercial Strategy
- How Roivant's patient support program and pricing strategy will impact LISRAYA's market positioning and revenue potential.